IDEXX Laboratories, Inc. (IDXX) Shares Sold by MERIAN GLOBAL INVESTORS UK Ltd

Share on StockTwits

MERIAN GLOBAL INVESTORS UK Ltd lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 738,411 shares of the company’s stock after selling 204,894 shares during the quarter. IDEXX Laboratories makes up 1.5% of MERIAN GLOBAL INVESTORS UK Ltd’s investment portfolio, making the stock its 16th largest holding. MERIAN GLOBAL INVESTORS UK Ltd’s holdings in IDEXX Laboratories were worth $165,108,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IDXX. LS Investment Advisors LLC increased its holdings in IDEXX Laboratories by 1.3% during the 1st quarter. LS Investment Advisors LLC now owns 3,424 shares of the company’s stock worth $766,000 after purchasing an additional 45 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of IDEXX Laboratories by 4.7% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,192 shares of the company’s stock valued at $222,000 after acquiring an additional 54 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of IDEXX Laboratories by 1.8% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 3,131 shares of the company’s stock valued at $583,000 after acquiring an additional 56 shares during the last quarter. Security Asset Management increased its holdings in shares of IDEXX Laboratories by 0.4% in the 4th quarter. Security Asset Management now owns 15,245 shares of the company’s stock valued at $2,836,000 after acquiring an additional 60 shares during the last quarter. Finally, SignalPoint Asset Management LLC increased its holdings in shares of IDEXX Laboratories by 5.1% in the 4th quarter. SignalPoint Asset Management LLC now owns 1,345 shares of the company’s stock valued at $250,000 after acquiring an additional 65 shares during the last quarter. Hedge funds and other institutional investors own 87.46% of the company’s stock.

A number of research analysts have recently commented on IDXX shares. Canaccord Genuity dropped their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, March 26th. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective on the stock in a report on Friday, May 3rd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $253.50.

IDXX opened at $250.00 on Friday. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $256.22. The stock has a market capitalization of $21.68 billion, a PE ratio of 58.84 and a beta of 0.97. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.13. The business had revenue of $576.06 million for the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.01 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current year.

In related news, VP Michael Lane sold 736 shares of the company’s stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $211.58, for a total value of $155,722.88. Following the completion of the sale, the vice president now directly owns 6,468 shares of the company’s stock, valued at approximately $1,368,499.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Rebecca M. Henderson sold 8,790 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $241.57, for a total value of $2,123,400.30. Following the completion of the sale, the director now directly owns 27,486 shares of the company’s stock, valued at $6,639,793.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,886 shares of company stock valued at $12,910,319. Insiders own 2.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://macondaily.com/2019/05/17/idexx-laboratories-inc-idxx-shares-sold-by-merian-global-investors-uk-ltd.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.